The effect of herbal medicine baicalin on pharmacokinetics of rosuvastatin, substrate of organic anion-transporting polypeptide 1B1

Clinical Pharmacology and Therapeutics

Volumn 83, Issue 3, 2008, Pages 471-476

  Fan, L ^a   Zhang, W ^a   Guo, D ^a   Tan, Z R ^a   Xu, P ^b   Li, Q ^a   Liu, Y Z ^a   Zhang, L ^a   He, T Y ^a   Hu, D L ^a   Wang, D ^a   Zhou, H H ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b Central South University   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BAICALIN; CYTOCHROME P450 2C9; ORGANIC ANION TRANSPORTER 1; ORGANIC ANION TRANSPORTING POLYPEPTIDE 1B1; PLACEBO; ROSUVASTATIN; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; HAPLOTYPE; HERB DRUG INTERACTION; HERBAL MEDICINE; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; CROSS-OVER STUDIES; DRUG INTERACTIONS; FLAVONOIDS; FLUOROBENZENES; HAPLOTYPES; HUMANS; MALE; MEDICINE, HERBAL; ORGANIC ANION TRANSPORTERS; PLANT PREPARATIONS; PYRIMIDINES; SUBSTRATE SPECIFICITY; SULFONAMIDES;

EID: 39449122141     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/sj.clpt.6100318     Document Type: Article

References (44)

1. Yim, J.S. et al. Metabolic activities of ginsenoside Rb1, baicalin, glycyrrhizin and geniposide to their bioactive compounds by human intestinal microflora. Biol. Pharm. Bull. 27, 1580-1583 (2004).
2. Zuo, F. et al. Metabolism of constituents in Huangqin-Tang, a prescription in traditional Chinese medicine, by human intestinal flora. Biol. Pharm. Bull. 25, 558-563 (2002).
3. Abe, K., Inoue, O. & Yumioka, E. Biliary excretion of metabolites of baicalin and baicalin in rats. Biol. Pharm. Bull. 38, 209-211 (1990).
4. Akao, T., Kawabata, K. & Yanagisawa, E. Baicalin, the predominant flavone glucuronide of scutellariae radix, is absorbed from the rat gastrointestinal tract as the aglycone and restored to its original form. J. Pharm. Pharmacol. 52, 1563-1568 (2000).
5. Lu, T. et al. Comparative pharmacokinetics of baicalin after oral administration of pure baicalin, Radix scutellariae extract and Huang-Lian-Jie-Du-Tang to rats. J. Ethnopharmacol. 110, 12-18 (2007).
6. Olsson, A.G., McTaggart, F. & Raza, A. Rosuvastatin: a highly effective new HMG-CoA reductase inhibitor. Cardiovasc. Drug Rev. 20, 303-308 (2002).
7. Olsson, A.G. et al. Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia. Am. Heart J. 144, 1044-1051 (2002).
8. Brown, W.V. et al. Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial. Am. Heart J. 144, 1036-1043 (2002).
9. Nezasa, K. et al. Liver-specific distribution of rosuvastatin in rats: comparison with pravastatin and simvastatin. Drug Metab. Dispos. 30, 1158 (2002).
10. Carswell, C.I., Plosker, G.L. & Jarvis, B. Rosuvastatin. Drugs 62, 2075-2085 (2002).
11. Brown, C.D.A., Windass, A., Bleasby, K. & Lauffart, B. Rosuvastatin is a high affinity substrate of hepatic organic anion transporter OATP1B1. Atherosclerosis 2, 90 (2001).
12. Simonson, S.G. et al. Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. Clin. Pharmacol. Ther. 76, 167-177 (2004).
13. Hsiang, B. et al. A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J. Biol. Chem. 274, 37161-37168 (1999).
14. Nakai, D. et al. Human liver-specific organic anion transporter, LST-1, mediates uptake of pravastatin by human hepatocytes. J. Pharmacol. Exp. Ther. 297, 861-867 (2001).
15. Shitara, Y., Itoh, T., Sato, H., Li, A.P. & Sugiyama, Y. Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporine A. J. Pharmacol. Exp. Ther. 304, 610-616 (2003).
16. Nishizato, Y. et al. Polymorphisms of OATP1B1 (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin. Pharmacol. Ther. 73, 554-565 (2003).
17. Mwinyi, J., Johne, A., Bauer, S., Roots, I. & Gerloff, T. Evidence for inverse effects of OATP1B1 (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics. Clin. Pharmacol. Ther. 75, 415-421 (2004).
18. Niemi, M. et al. High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C OATP1B1). Pharmacogenetics 14, 429-440 (2004).
19. Schneck, D.W. et al. The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin. Pharmacol. Ther. 75, 455-463 (2004).
20. Ho, R.H. et al. Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology 130, 1793-1806 (2006).
21. Cooper, K.J., Martin, P.D., Dane, A.L., Warwick, M.J., Schneck, D.W. & Cantarini, M.V. The effect of fluconazole on the pharmacokinetics of rosuvastatin. Eur. J. Clin. Pharmacol. 58, 527-531 (2002).
22. Martin, P.D. et al. Metabolism, excretion and pharmacokinetics of rosuvastatin. Clin. Ther. 25, 2822-2835 (2003).
23. McCormick, A.D. et al. ZD4522 - an HMG-CoA reductase inhibitor free of metabolically mediated drug interactions: metabolic studies in human in vitro systems. J. Clin. Pharmacol. 40, 1055 (2000).
24. Martin, P.D., Kemp, J., Dane, A.L., Warwick, M.J. & Schneck, D.W. No effect of rosuvastatin on the pharmacokinetics of digoxin in healthy volunteers. J. Clin. Pharmacol. 42, 1352-1357 (2002).
25. Cooper, K.J., Martin, P.D., Dane, A.L., Warwick, M.J. & Schneck, D.W. Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin. Br. J. Clin. Pharmacol. 55, 94-99 (2003).
26. Bergman, E. et al. Biliary secretion of rosuvastatin and bile acids in humans during the absorption phase. Eur. J. Pharm. Sci. 29, 205-214 (2006).
27. Zhang, W. et al. Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. Clin. Chim. Acta 373, 99-103 (2006).
28. Lee, E. et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin. Pharmacol. Ther. 78, 330-341 (2005).
29. Catz, C. & Yaffe, S.J. Pharmacological modification of bilirubin conjugation in the newborn. Am. J. Dis. Child. 104, 516-517 (1962).
30. Ritter, J.K., Kessler, F.K., Thompson, M.T., Grove, A.D., Auyeung, D.J. & Fisher, R.A. Expression and inducibility of the human bilirubin UDP-glucuronosyltransferase UGT1A1 in liver and cultured primary hepatocytes: evidence for both genetic and environmental influences. Hepatology 30, 476-484 (1999).
31. Kamisako, T. et al. Recent advances in bilirubin metabolism research: the molecular mechanism of hepatocyte bilirubin transport and its clinical relevance. J. Gastroenterol. 35, 659-664 (2000).
32. Jansen, P.L., Bosma, P.J. & Chowdhury, J.R. Molecular biology of bilirubin metabolism. Prog. Liver Dis. 13, 125-150 (1995).
33. Cui, Y., König, J., Leier, I., Buchholz, U. & Keppler, D. Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6. J. Biol. Chem. 276, 9626-9630 (2001).
34. Briz, O., Serrano, M.A., Macias, R.R., Gonzalez-Gallego, J. & Marin, J.J.G. Role of organic anion-transporting polypeptides OATP-A OATP1B1 and OATP-8, in the human placenta-maternal tandem excretory pathway for foetal bilirubin. Biochem. J. 371, 897-905 (2003).
35. Campbella, S.D., de Moraisa, S.M. & Xu, J.J. Inhibition of human organic anion transporting polypeptide OATP 1B1 as a mechanism of drug-induced hyperbilirubinemia. Chem. Biol. Interact. 150, 179-187 (2004).
36. Ieiri, I. et al. Influence of common variants in the pharmacokinetic genes (OATP-C, UGT1A1, and MRP2) on serum bilirubin levels in healthy subjects. Hepatol. Res. 30, 91-95 (2004).
37. Chen, C. et al. Differential interaction of 3-hydroxy-3- methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab. Dispos. 33, 537-546 (2005).
38. Treiber, A., Schneiter, R., Delahaye, S. & Clozel, M. Inhibition of organic anion transporting polypeptide-mediated hepatic uptake is the major determinant in the pharmacokinetic interaction between bosentan and cyclosporin A in the rat. J. Pharmacol. Exp. Ther. 308, 1121-1129 (2004).
39. Dresser, G.K. et al. Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin. Pharmacol. Ther. 71, 11-20 (2002).
40. Dresser, G.K., Kim, R.B. & Bailey, D.G. Effect of grapefruit juice volume on the reduction of fexofenadine bioavailability: possible role of organic anion transporting polypeptides. Clin. Pharmacol. Ther. 77, 170-177 (2005).
41. Wang, X., Wolkoff, A.W. & Morris, M.E. Flavonoids as a novel class of human organic anion-transporting polypeptide OATP1B1 (OATP-C) modulators. Drug Metab. Dispos. 33, 1666-1672 (2005).
42. Wang, S.L., Huang, J., Lai, M.D. & Tsai, J.J. Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese. Pharmacogenetics 5, 37-42 (1995).
43. Zhang, Y., Zhong, D., Si, D., Guo, Y., Chen, X. & Zhou, H. Lornoxicam pharmacokinetics in relation to cytochrome P450 2C9 genotype. Br. J. Clin. Pharmacol. 59, 14-17 (2005).
44. Stephens, M., Smith, N.J. & Donnelly, P. A new statistical method for haplotype reconstruction from population data. Am. J. Hum. Genet. 68, 978-989 (2001).